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Abstract
Introduction
Uptake of psychotropic medication has been previously used as a proxy for assessing the prevalence
of population mental health morbidity. However, it is not known how this compares with estimates
derived from population screening tools.
Objective
To compare estimates of psychiatric morbidity derived by a validated screening instrument of psy-
chiatric morbidity and a self-reported medication uptake measure.
Methods
This study used data from two recent population-wide health surveys in Northern Ireland, a coun-
try (UK) with free health services and no prescription charges. The psychiatric morbidity of 7,489
respondents was assessed using the GHQ-12 and self-reported use of medication for stress, anxiety
and depression (sDAS medication).
Results
Overall, 19% of respondents were defined as ‘cases’ and 14.3% were taking sDAS medication. Gen-
erally, the two methods identified the same population distributions of characteristics that were
associated with psychiatric morbidity though nearly as many non-cases as cases received sDAS med-
ication (46.4% vs. 53.6%). A greater proportion of women and older people were identified as cases
according to sDAS medication use, while no such variation was observed between socio-economic
status and method of assessment.
Conclusions
This study indicates that these two methods of assessing population psychiatric morbidity provide
similar estimates, despite potentially identifying different individuals as cases. It is important to
note that different health care systems might be linked to variations in obstacles when accessing and
using health care services.
Highlights
• There was a reasonable correspondence between the different methods of assessment.
• A greater proportion of women and older people were identified as cases through the self-
reported use of medication.
• An almost equal amount of GHQ-12 cases and non-cases reported being in receipt of medica-
tion.
Introduction
Mental disorders constitute a major public health issue due
to their economic, psychological and social impact on pop-
ulations and it is predicted that depression, which is ranked
second in the Global Burden of Disease studies, will overtake
ischaemic heart disease soon as the major cause of morbidity
throughout the world [1].
Arguably, the most commonly used method of assessing
population mental health is to undertake a population-wide
survey using a recognised instrument for assessing the preva-
lence of psychiatric morbidity. Examples of such instruments
include the World Health Organisation (WHO) Composite In-
ternational Diagnostic Interview (CIDI) and the Clinical In-
terview Schedule-Revised (CIS-R), which have been used re-
spectively in the National Comorbidity Survey in the US [2]
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and the British Psychiatry Morbidity Survey [3]. These have
been developed from clinical tools and produce assessments
for each survey respondent according to the definitions and
criteria of ICD-10 and/or DSM-IV [4,5,6]. Data produced by
these studies are recognised to be of high quality and repetition
at regular intervals can produce evidence of temporal trends
in psychiatric burden in society [7]. However, this approach
is resource intensive, time-consuming for respondents and re-
quires clinical application or specialist interviewer training [2].
Collectively, these pressures on resources may lead to reduced
sample sizes thereby producing further problems with respect
to generalisability [3]. Therefore, most large-scale population
surveys tend to use self-report assessments that have been val-
idated against more clinically-based assessments and, so, may
be undertaken as part of general health surveys [8,9]. One ex-
ample is the General Health Questionnaire (GHQ) [10] which
has previously used as a means of assessing “psychiatric case-
ness” in the population [11]. However, even these approaches
have recognised additional limitations. The majority of os-
tensibly population-wide studies are based on people who are
resident in private households and, consequentially, they do
not include homeless people or individuals in institutionalised
settings, thus omitting a large proportion of the population
with a high prevalence of physical and psychiatric problems
[12,13]. Furthermore, response rates to general population
surveys tend to be moderate and they have been declining
over recent decades [14,15]; non-response bias is an ongoing
concern and as it is higher amongst young males [16,17], peo-
ple with lower socio-economic status [18], or residing in urban
centres [19], there may be difficulties generalising findings on
specific sub-samples to the population as a whole.
The increased availability of secondary data related to the
management and treatment of psychiatric disorders has pre-
sented alternative ways to examine population level mental
health. Many studies originating in Scandinavian and the
Nordic countries [20] have previously used hospitalisation rates
[21,22], as well as, individual uptake of psychotropic medica-
tion to examine a range of factors, including maternal and
pre-natal factors related to attention-deficit/hyperactivity dis-
order in children [23,24], factors related to impaired psycholog-
ical health in adolescents and younger adults [25], area effects
on psychiatric morbidity [26], the effects of working condi-
tions and early retirement [27,28] and the prevalence and dif-
ferences in poor mental health across refugees and migrants
[29]. Medical records have also been used in validity studies
of self-reported medication use, with reports of good agree-
ment and specificity being noted between the two measures,
especially in chronically used medicines [30].
The benefits of using psychotropic medication as a proxy
for psychological health include: population-wide coverage and
face validity, assuming that the available treatment is in ac-
cordance with recommendations [31]. The limitations of this
approach include the potential for confounding by the access
to and use of health services [32] and variability in the avail-
ability and use of alternative non-pharmacological treatments.
Non-specificity of use may also be an issue as in some cases
psychotropic medication might be prescribed for a different
non-psychiatric condition, such as the occasional prescription
of anti-depressants to patients experiencing pain [33]. There
is a need, therefore, to investigate these two commonly used
means of screening for psychiatric morbidity and the nature
and degree to which they provide similar prevalence estimates
and population distributions. Although both methodologi-
cal approaches have been explored, and their strengths and
caveats have been previously highlighted in terms of the gener-
alisability of the results, they have only been compared against
more established measures, e.g. comparison between CIS-R
and SCAN [4].
This is the first comparative, analytical study (we are aware
of) that directly compares these two methods of measuring
population psychiatric morbidity in the same study. Using a
large population-based sample in Northern Ireland, we aimed
to: i) provide a comparison between estimates of psychiatric
morbidity as assessed by a self-reported medication use mea-
sure and a recognised psychiatric morbidity questionnaire and
ii) compare the characteristics of those classified as cases by
each measure.
Methods
The data are derived from the two most recent waves of the
Northern Ireland Health Survey (2011/12 and 2013/14). This
is a general population interview-based survey designed to pro-
vide a regular source of information on a wide range of health
issues and is based on a random sample of approximately 5800
addresses drawn from a centralised list of land and property
services in Northern Ireland. The fieldwork includes an in-
terview with each resident at the address aged 16 and over,
which was undertaken by using computer assisted personal in-
terviewing (CAPI) or where appropriate computer assisted self
interviewing (CASI) between April of one year until March of
the next year. The response rates were 65% and 66% respec-
tively for these survey waves [34]. Northern Ireland has free
at-the-point-of-use healthcare services for individuals who are
registered for a health card.
Cohort characteristics
Respondent characteristics were derived from survey re-
sponses, and covered an array of demographic and socio-
economic characteristics and behavioural factors including age
(in 10-year age-groups from 16 to 65+), sex and marital sta-
tus (three groups: married, cohabiting or civil partnership;
never married; separated, divorced, or widowed). Three indi-
cators of socio-economic status were measured; at the indi-
vidual level, these were housing tenure (owner occupier, social
renter, private renter), and social class based on the National
Statistics-Socioeconomic Classification (NS-SEC) [35]; and at
an area level, the Northern Ireland Index of Multiple Depriva-
tion (a measure of deprivation derived largely from administra-
tive data sources for 890 small census tracts with an average
population of circa 1900 [36]). Long standing illness was as-
sessed as a positive response to questions about the presence
of ‘any physical or mental health condition or illnesses last-
ing or expected to last 12 months or more’, which was then
classified as ‘limiting’ if it reduced the ‘ability to carry out
day-to-day activities’. Cigarette smoking (grouped as current
smoking or not) and drinking were also included (non-drinker,
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drinking below recommended limits, drinking above recom-
mended limits that were in place at the time of the survey
– defined as 14 units per week for women and 21 units per
week for men) as behavioural characteristics of the sample.
Measures of psychiatric morbidity included GHQ-12 scores and
medication uptake and will be described below.
General Health Questionnaire caseness
The 12-item version of the General Health Questionnaire
(GHQ) is a widely used measure of minor psychiatric disorders
in the general population [10,37,38] that captures symptoms of
anxiety, depression, social dysfunction, and loss of confidence
[39]. It was developed as a screening instrument for use in gen-
eral practice, but it has been used commonly for many years
in survey studies. For each of the twelve items/symptoms,
respondents were asked whether the symptom was present,
not at all, same as usual, more than usual, or much more
than usual, and these response options were scored 0,0,1,1,
respectively. The scores are summed with high scores indi-
cating the presence of psychiatric morbidity. Responses may
be dichotomised by using a cut-off score of four or more to
define people as ‘cases’ and scores 0-3 as non-cases [38]. This
definition has been validated by standardised psychiatric in-
terviews and is strongly indicative of depression and anxiety
[40,41]. The GHQ-12 was among a series of questionnaires
administered to all participants in both survey waves.
Use of sDAS medication
At the end of the GHQ-12 section, a further question was
asked about pharmacological treatment for minor psychiatric
conditions: ‘Are you taking any medicine or tablets for stress,
anxiety or depression?’ with responses being ‘yes’ or ‘no’.
In the rest of this paper we call this “sDAS medication” for
brevity.
Analytical approach
The two survey waves were combined to add to the stability of
the data and statistical models were constructed and tested to
examine differences and the general robustness across the sur-
veys (full models available on request). Categorisation of the
responses to the GHQ-12 define respondents as either cases or
non-cases and the question on sDAS medication is also binary;
respondents, therefore, fall into one of four categories as shown
in Figure 1. Cells ‘C’ and ‘D’ represent respondents defined as
GHQ-12 cases; cells ‘A’ and ‘B’ are GHQ-12 non-cases. Re-
spondents in cell ‘A’ (the majority of the population) are not
a GHQ-12 case and not using sDAS medication. Descriptive
statistics were used to describe the proportions and character-
istics of respondents falling into each of the four cells. The
data were weighted by demographic characteristics of the in-
terviewees (including age and sex) in order to reflect the com-
position of the general population in Northern Ireland. The
non-response weights were created by the data custodians at
the Information and Analysis Directorate at the Department
of Health and the UK Data Archive, aiming to control for
respondent characteristics related to survey response rates.
Next, two separate logistic regression models were con-
ducted, one with GHQ-12 case as the dependent variable,
the second with ‘on medication’ as the dependent variable
or outcome. This analysis compared the profiles of psychiatric
morbidity that were produced by each assessment measure.
The reference categories for each regression analysis were cells
‘A’+’B’ for GHQ-12 cases and ‘A’+’C’ for sDAS medication
use. Additional sensitivity analyses were undertaken compar-
ing GHQ-12 cases and sDAS medication use against cell ‘A’
alone i.e. a common comparator comprising people who were
not defined as cases and were not on medication.
Results
A total of 7,489 respondents over the 2 years completed the
GHQ-12 questionnaire and answered the question about sDAS
medication; 6.7% (n=539) had missing values in either out-
come variable and were excluded from the analysis though
they did not vary significantly from the final sample. A total
of 1,422 (19%) had GHQ-12 scores of four or more indicating
a high likelihood of psychiatric morbidity; 16.8% were male
and 20.4% were female. In terms of sDAS medication uptake,
1,072 (14.3%) individuals appeared to receive and use sDAS
medication; women showed a higher prevalence of medication
use (16.9% and 10.5% respectively). These proportions were
stable over the two survey waves.
Table 1 describes the socio-demographic and behavioural
characteristics of the four types of respondent described in
Figure 1. People who presented with psychiatric morbidity
(defined by being a GHQ-12 case or being on sDAS medi-
cation) were more likely to be female, unmarried, of lower
socio-economic status, in poorer physical health and currently
smoking. This pattern was more pronounced among GHQ-12
cases who used sDAS medication - they were twice as likely
to be divorced, separated or widowed (24.9% versus 12.2%),
approximately half as likely to be in professional classes, three
times as likely to be living in social housing (35.8% versus
12.6%), twice as likely to be a smoker, and five times as likely
to have a limiting long-standing illness (63.5% versus 11.1%)
(compared to respondents in cell A – non GHQ-12 cases who
were not on medication). The profile of respondents who were
a GHQ-12 case or on medication lay between these categories.
The correspondence between the number of individuals
that were identified as cases by the two measures was fur-
ther investigated through the use of a GHQ-12 variable with
three categories (0, 1-3 and >4). There was a strong graded
relationship between GHQ-12 caseness and medication use -
40.3% percent of GHQ-12 cases (with a score of 4 or more)
used medication compared to 13.4% of people who scored 1-3
and 5.4% with GHQ-12 scores of zero. However, this lower
percentage multiplied by the greater number of people with
low GHQ-12 scores indicates that there was nearly an equal
number of sDAS medication users amongst GHQ-12 cases as
non-cases (N=574; 53.6% vs N=498; 46.4%). Indeed, about
one-in-five (20.1%) of sDAS medication users had GHQ-12
scores of zero.
Table 2 shows the results of the regression analyses. There
were no appreciable differences between the two waves of the
survey in terms of sDAS medication uptake or GHQ-12 case-
ness (full models available on request) and, thus, the results
of the combined waves are presented. Overall, each mea-
sure confirmed the general demographic, socio-economic and
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Figure 1: Relationship between GHQ-12 caseness and sDAS medication use
Figure 2: Relationship between GHQ-12 scores (0, 1-3 and >4) and use of psychotropic medication
4
Tseliou, F et. al. / International Journal of Population Data Science (2018) 3:5
Table 1: Characteristics of population subgroups classified according to GHQ-12 caseness and sDAS medication
GHQ non-case GHQ non-case GHQ case GHQ case
sDAS Medication-No sDAS Medication-Yes sDAS Medication-No sDAS Medication-Yes
Number 5569 498 848 574
Age
16-24 946 (17.0) 25 (5.1) 163 (19.2) 51 (8.9)
25-34 1030 (18.5) 60 (12.1) 148 (17.4) 77 (13.5)
35-44 946 (17.0) 94 (18.8) 129 (15.2) 123 (21.4)
45-54 908 (16.3) 104 (20.8) 151 (17.9) 150 (26.1)
55-64 698 (12.5) 110 (22.2) 106 (12.5) 104 (18.0)
65+ 1041 (18.7) 105 (21.0) 151 (17.9) 69 (12.0)
Sex
Female 3237 (58.1) 360 (72.5) 522 (61.5) 400 (69.7)
Male 2,332 (41.9) 138 (27.5) 326 (38.5) 174 (30.3)
Marital status
Married 1959 (35.2) 124 (24.7) 340 (40.1) 198 (34.4)
Never married 2929 (52.6) 268 (53.9) 364 (42.9) 233 (40.7)
Sep/Wid/Divorced 681 (12.2) 106 (21.3) 144 (17.0) 143 (24.9)
Social class
Higher 628 (11.2) 42 (8.4) 73 (8.6) 42 (7.3)
Intermediate 2275 (40.9) 188 (37.9) 341 (40.2) 172 (30.0)
Lower/ other 2666 (47.9) 268 (53.7) 434 (51.2) 360 (62.7)
Housing tenure
Owner 3926 (70.5) 312 (62.8) 503 (59.3) 254 (44.3)
Social renter 702 (12.6) 104 (20.8) 175 (20.6) 206 (35.8)
Private renter 941 (16.9) 82 (16.4) 170 (20.1) 114 (19.9)
Area deprivation
Most deprived 943 (16.9) 107 (21.4) 199 (23.5) 176 (30.6)
More deprived 1041 (18.7) 99 (19.9) 181 (21.3) 130 (22.7)
Average 1249 (22.4) 108 (21.7) 170 (20.1) 100 (17.5)
Less deprived 1192 (21.4) 93 (18.6) 151 (17.8) 101 (17.6)
Least deprived 1144 (20.5) 91 (18.4) 147 (17.3) 67 (11.7)
%LLSI 621 (11.1) 176 (35.3) 264 (31.1) 364 (63.5)
Smoking status
Current smoker 1107 (19.9) 142 (28.6) 264 (31.1) 248 (43.2)
Drinking status
Below Rec. limits 3336 (60.0) 263 (53.1) 477 (56.5) 276 (48.3)
Above Rec. limits 961 (17.3) 92 (18.7) 160 (19.0) 113 (19.8)
NB: Data represent population weighted numbers and percentages within each group.
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Table 2: A comparison of the characteristics of those presenting as cases against non-cases, as defined by (i) GHQ-12 only and
(ii) assessment using sDAS medication only. Data represent Odds Ratios and 95% Confidence Intervals from logistic regression
models.
GHQ GHQ sDAS Medication sDAS Medication
adjusted age/sex fully adjusted adjusted age/sex fully adjusted
Age
16-24 1 1 1 1
25-34 0.94 (0.73-1.21) 0.90 (0.69-1.19) 1.62 (1.12-2.34) 1.63 (1.11-2.40)
35-44 1.11 (0.87-1.41) 1.04 (0.79-1.38) 2.82 (2.00-3.98) 2.95 (2.03-4.31)
45-54 1.38 (1.09-1.74) 1.14 (0.86-1.51) 3.50 (2.50-4.90) 3.21 (2.20-4.69)
55-64 1.20 (0.94-1.52) 0.85 (0.63-1.14) 3.90 (2.78-5.48) 3.25 (2.20-4.79)
65+ 0.87 (0.69-1.10) 0.49 (0.37-0.66) 2.07 (1.47-2.91) 1.32 (0.89-1.97)
Sex
Male 1 1 1 1
Female 1.27 (1.13-1.42) 1.23 (1.08-1.40) 1.80 (1.58-2.05) 1.89 (1.64-2.19)
Marital status
Never married 1 1 1 1
Married 0.63 (0.54-0.73) 0.88 (0.74-1.03) 0.64 (0.54-0.76) 0.92 (0.76-1.11)
Sep/Wid/Divorced 1.25 (1.04-1.50) 1.12 (0.91-1.37) 1.27 (1.04-1.55) 1.13 (0.91-1.40)
Social class*
Higher 1 1 1 1
Intermediate 1.13 (0.92-1.39) 1.08 (0.87-1.34) 1.09 (0.87-.138) 1.05 (0.82-1.34)
Lower/ Other 1.65 (1.36-2.01) 1.11 (0.90-1.38) 1.89 (1.51-2.36) 1.28 (1.01-1.63)
Housing tenure
Owner 1 1 1 1
Social renter 2.86 (2.49-3.28) 1.51 (1.28-1.79) 3.01 (2.59-3.50) 1.56 (1.30-1.88)
Private renter 1.78 (1.51-2.11) 1.31 (1.09-1.57) 2.10 (1.74-2.53) 1.55 (1.26-1.90)
Area deprivation**
Most deprived 1 1 1 1
More deprived 0.76 (0.65-0.90) 1.00 (0.83-1.20) 0.73 (0.61-0.88) 0.96 (0.78-1.17)
Average 0.55 (0.46-0.65) 0.82 (0.68-0.99) 0.57 (0.48-0.69) 0.88 (0.72-1.08)
Less deprived 0.52 (0.44-0.66) 0.87 (0.72-1.06) 0.54 (0.48-0.69( 0.94 (0.76-1.16)
Least deprived 0.47 (0.39-0.56) 0.87 (0.71-1.06) 0.44 (0.36-0.54) 0.87 (0.69-1.09)
LLSI
No 1 1 1 1
Yes 6.46 (5.67-7.37) 5.37 (4.68-6.15) 6.13 (5.34-7.04) 4.99 (4.32-5.77)
Smoking status
Non-smoker 1 1 1 1
Current smoker 2.15 (1.91-2.43) 1.48 (1.29-1.70) 2.13 (1.86-2.44) 1.36 (1.17-1.59)
Drinking status
Non-drinker 1 1 1 1
Below Rec. limits 0.70 (0.61-0.79) 0.92 (0.80-1.07) 0.66 (0.57-0.76) 0.89 (0.76-1.04)
Above Rec. limits 0.85 (0.72-1.02) 1.02 (0.84-1.24) 0.92 (0.76-1.11) 1.15 (0.93-1.42)
*Social class was alternatively tested as a linear variable in addition to the categorical results presented above: OR 1.35 95%CI
1.24-1.47; OR 1.04 95%CI 0.95-1.15; OR 1.51 95%CI 1.37-1.66; OR 1.16 95%CI 1.05-1.29 respectively.
**Area deprivation was alternatively tested as a linear variable in addition to the categorical results presented above: OR 0.82
95%CI 0.79-0.86; OR 0.96 95%CI 0.91-1.00; OR 0.82 95%CI 0.79-0.86; OR 0.97 95%CI 0.92-1.02 respectively.
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behavioural correlates with psychiatric morbidity described in
Table 1, though there were some differences particularly re-
lating to age and sex. The sex difference in the prevalence of
psychiatric morbidity was more visible according to medication
use than GHQ-12 caseness (OR 1.89; 95%CI: 1.64-2.19; OR
1.23; 95%CI: 1.08-1.40 respectively for females compared to
males). The likelihood of reporting psychiatric morbidity as
defined by sDAS medication use increased markedly with age
but much less so for GHQ-12 caseness; for example, compared
to those aged 16-24 the likelihood of being defined as report-
ing psychiatric morbidity at age 55-64 was OR 0.85; 95%CI:
0.63-1.14 according to GHQ-12 and OR; 3.25 95%CI: 2.20-
4.79 according to medication use. It could be argued that this
is because the use of psychotropic medication is not recom-
mended at younger ages [42,43], but the increased medication
use with age persists even with a 25-34 reference (results avail-
able on request). Both measures captured the protective ef-
fect of marriage when compared to other categories of marital
status, with the trend being slightly stronger with the use of
GHQ, although it didn’t reach significance for either measure
(OR 0.88; 95%CI: 0.74-1.03 and OR 0.92; 95%CI: 0.76-1.11
respectively).
There were very small differences in the association be-
tween socio-economic status and psychiatric morbidity with
both measures showing the expected prevalence of psychiatric
morbidity with increased disadvantage, though the gradients
were a little steeper when psychiatric morbidity was assessed
using uptake of sDAS medication. Being limited by a long-
term condition, as measured by LLSI was strongly associated
with psychiatric morbidity and the inclusion of this variable
in the fully adjusted models greatly attenuated the associa-
tion between psychiatric morbidity and socioeconomic status
suggesting that much of the social gradients in mental health
are linked to the social gradients in physical health. Current
smoking was associated with an increased likelihood of psychi-
atric morbidity with both assessments of caseness producing
similar increases in risk compared to non-smokers. Although
those drinking alcohol at below the recommended safe limits
were less likely to experience psychiatric morbidity than either
non-drinkers or those drinking more than the recommended
limits, these differences largely disappeared with further ad-
justment for socio-economic status and measures of physical
health, with similar patters produced by GHQ-12 and uptake
of sDAS medication.
A sensitivity analysis compared individuals presenting with
psychiatric morbidity (defined by GHQ-12 caseness or the use
of sDAS medication) with non GHQ-12 cases who did not
use medication (full models available on request). Again, the
main differences were in terms of age with stronger effects be-
ing observed when sDAS medication uptake was used, while
variations between measures remained rather subtle, as those
defined as GHQ-12 cases were similar in both models, with
the exception of gender (GHQ: OR 1.32; 95%CI 1.15-1.50
and Medication: OR 1.90; 95%CI 1.63-2.21 respectively).
Discussion
This study found that about one-third more people were de-
fined as experiencing psychiatric morbidity when a definition
based on GHQ-12 caseness was used rather than sDAS medica-
tion usage (19% and 14% respectively). This variation might
be linked to the fact that people with more severe symptoms
are more likely to receive or use psychotropic medication [31]
or that a proportion might receive non-pharmacological ther-
apies, though the availability and use of these services are
relatively low in Northern Ireland.
Interestingly, while there was some correspondence be-
tween overall GHQ-12 caseness and sDAS medication use, it
was clear that the two measures captured different population
segments in their respective psychiatric morbidity assessments.
Only 40% of GHQ-12 cases were defined as cases according to
sDAS medication use; and only 54% of people on sDAS medi-
cation had a GHQ-12 cut-off score of 4 or more. Furthermore,
there were nearly as many people on medication who were not
GHQ-12 cases as there were cases who reported using medica-
tion. A possible explanation for this finding is that the medi-
cation may be being used to treat presumed minor psychiatric
disorders. Due to the phrasing of the relevant survey question,
respondents may have reported non-prescribed ‘medication’ in-
cluding alternative medicine or therapy. The finding may also
represent an over-prescribing trend by GPs. A relatively recent
meta-analysis showed that while GPs were good at ruling out
appropriately a diagnosis of depression, the modest prevalence
of depression in primary care leads to a high proportion of mis-
classifications and the potential for over treatment with a rate
of false positives that outnumber true positives by about 50%
[44,45]. It is possible also that the finding represents a group
of patients who have been correctly diagnosed and who are
being appropriately treated with a medication that has been
effective in treating their symptoms and, therefore, in lower-
ing their GHQ-12 scores. This raises the interesting question
as to whether non-GHQ cases in receipt of medication should
be added to the stated prevalence of psychiatric disorders i.e.
that the true prevalence of psychiatric conditions is the sum
of people with a GHQ-12 score above the threshold plus peo-
ple who are using medication for a psychiatric disorder. This
is analogous to the assessment of prevalence of raised blood
pressure or of diabetes in the population where it is standard
practice to add the proportion above the designated cut-off
and the proportion on medication (but below the threshold) to
give the overall population prevalence. This methodology was
used in the British Psychiatric Morbidity Survey for estimating
the prevalence of psychosis but not the prevalence of neurotic
disorders [3]. The addition of respondents on sDAS medication
who were below GHQ-12 threshold scores to respondents who
were classified as GHQ-12 cases would increase the prevalence
of psychiatric morbidity by 6.6% bringing the overall preva-
lence to 25.6% (with 8.5% of males being cases and 17.2%
of females being cases, respectively). The inclusion of people
managed with non-pharmacological interventions could pro-
vide a more comprehensive assessment of the true prevalence
of psychiatric conditions, in the absence of a tool that can ac-
curately identify mental illness masked by medication uptake.
However, a third indicator of mental ill-health might lead to
further confusion by introducing additional differences in the
numbers and characteristics of people in receipt of psycholog-
ical therapies.
A greater proportion of women and older people would be
categorised as cases if the assessment was based on usage of
sDAS medication than on GHQ-12 scores. This is likely to be
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linked to a combination of factors related to the differential use
of primary care services aligned with treatment- or help-seeking
behaviours and a greater propensity to report emotional and
psychological symptoms. Primary care utilisation is related to
age and sex, as older people and women are more likely to
attend their GP, and women are also more likely to present
to mental health services [46-49]. This is supported by the
higher proportion of women than men with GHQ-12 scores of
4 or more on medication (45.4% and 35.7% respectively). It
is possible that differences in adherence rates which are known
to be related to age might also contribute to these age gradi-
ents [50,51] along with a reluctance to prescribe psychotropic
medication in younger people [42].
In the current study both the GHQ-12 and uptake of sDAS
medication produced fairly similar rates of psychiatric morbid-
ity according to socio-economic status and behavioural char-
acteristics. However, we would urge some caution in terms of
generalisation as the current study was undertaken in a coun-
try where access to primary care services is free at the point of
use and where there were no charges for prescribed medication.
It is possible that significant differences between the measures
may be apparent in countries where patients have to pay to
attend their GP and/or pay for their medicines. However,
systematic variation between GPs in their ability to diagnose
minor psychiatric disorders such as depression in primary care
should also be considered [43].
It is important to consider the strengths and limitations of
the study. The data were drawn from large general household
surveys with relatively good response rate and although the
exact nature of medication was not independently verified and
it is possible that some respondents may have misunderstood
or misreported why they were on the medication. The ques-
tions relating to GHQ-12 and to sDAS medication were asked
together, so, the potential for differential recall was reduced,
though the effects of selective reporting due to stigma might
have been a factor. It is also recognised that an increasing pro-
portion of psychotropic medication, including antidepressants,
is used to treat non-psychiatric conditions [52] and there has
been some work to produce algorithms to identify the subset
of medicine users who really present with psychiatric disorders
[53]. However, this is less of an issue here as respondents
were asked specifically about medication for ‘stress, anxiety or
depression’; though the inclusion of the term “stress” in the
assessment of medication use might reduce the strength of
the findings through the potential inclusion of non-psychiatric
specific indicators. The GHQ-12, as with most screening in-
struments, is not a perfect indicator of psychiatric morbidity
at an individual level and with a sensitivity and specificity in
the region of 70-80% when compared to more detailed stan-
dards [38] a degree of random misclassification at the indi-
vidual level is to be anticipated. The expectation is that the
instrument correctly quantifies the proportions and character-
istics of those affected in the overall population though some
studies have indicated systematic ascertainment biases in the
GHQ-12 leading to higher estimations amongst the more af-
fluent [54]. We were not able to examine the variation across
ethnicity and migration status due to small numbers and this
may be important as some studies have suggested that lan-
guage difficulties can lead to reduced access to health services
and lower levels of prescribing for anxiety and depression [55].
Conclusions
In summary, this research has confirmed that these two ap-
proaches to the assessment of the psychiatric conditions of the
population will produce systematic variation in the magnitude
of the overall effect of psychiatric morbidity and in the char-
acteristics of those affected. It is important to reiterate that
commonly used methods are imperfect; thus, public health
and mental health researchers and planners need to be mind-
ful of the strengths and caveats associated with each method
and the interpretation of their results. Further consideration
should be given to whether or not the group with low GHQ-12
scores who are on medication should be included in the overall
assessment of psychiatric disorders at a population level.
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